- Clone:
- REAL174
- Type of antibody:
- Releasable antibodies, Primary antibodies, Recombinant antibodies
- Applications:
- FC, MICS, IF, IHC Glossary
- Select a conjugate:
- Select a size:
Related products for CD5 Antibody, anti-mouse, REAlease®
Clone REAL174 is an antibody fragment derived from the full CD5 antibody molecule. It displays no binding to Fc receptors. The recombinantly engineered antibody fragments are multimerized to form the REAlease Complex to bind markers with high avidity.
Clone REAL174 recognizes the mouse CD5 antigen, a 67 kDa single-pass type I membrane protein which is also known as lymphocyte antigen 1 (Ly-1). CD5 is expressed by a majority of thymocytes, mature T cells, and a subset of B cells. The expression of CD5 by a small B cell subset characterizes a developmentally and functionally distinct lineage of B cells called B-1a cells. CD5 plays a role in the interaction of T and B cells and is a counter-receptor for CD72.
The REAlease Kits consist of the respective fluorochrome-conjugated REAlease Complexes and the REAlease Support Kit for removal of the REAlease Complexes and optional relabeling with different fluorochrome-conjugated REAlease Complexes.
Ly-1, Ly-12, Ly-A, Lyt-1, T1, Tp67
Technical specifications
To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.
Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.
- Lundy, S. K. et al. (2014) Characterization and activity of Fas ligand producing CD5+ B cells. Methods Mol. Biol. 1190: 81-102
- Tarakhovsky, A. et al. (1995) A role for CD5 in TCR-mediated signal transduction and thymocyte selection. Science 269 (5223): 535-537
- Efanov, A. et al. (2010) CD5+CD23+ leukemic cell populations in TCL1 transgenic mice show significantly increased proliferation and Akt phosphorylation. Leukemia 24 (5): 970-975